Last reviewed · How we verify

Single intravenous injection of Tegileridine Fumarate

Second Affiliated Hospital, School of Medicine, Zhejiang University · FDA-approved active Small molecule Quality 1/100

Single intravenous injection of Tegileridine Fumarate is a Small molecule drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University. It is currently FDA-approved.

At a glance

Generic nameSingle intravenous injection of Tegileridine Fumarate
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Single intravenous injection of Tegileridine Fumarate

What is Single intravenous injection of Tegileridine Fumarate?

Single intravenous injection of Tegileridine Fumarate is a Small molecule drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who makes Single intravenous injection of Tegileridine Fumarate?

Single intravenous injection of Tegileridine Fumarate is developed and marketed by Second Affiliated Hospital, School of Medicine, Zhejiang University (see full Second Affiliated Hospital, School of Medicine, Zhejiang University pipeline at /company/second-affiliated-hospital-school-of-medicine-zhejiang-university).

What development phase is Single intravenous injection of Tegileridine Fumarate in?

Single intravenous injection of Tegileridine Fumarate is FDA-approved (marketed).

Related